HG (33 mM) treatment, simulating diabetes in vitro, significantly increased the expression levels of COL1a, COL3a, TGF-β, and α-SMA in CFs (Fig. 3A-C; G-K). This evidence concerns the gene TGFB1 and diabetes mellitus.